We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

3 hedge funds and large institutions have $5K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more capital invested

Capital invested by funds: $4K → $5K (+$1K)

63% less funds holding

Funds holding: 8 → 3 (-5)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
3
Holders Change
-5
Holders Change %
-62.5%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FWM
Focused Wealth Management
New York
+$758

Top Sellers

Rank Fund Capital Flow
1
CCB
Cutter & Co Brokerage
Missouri
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$4K – – –
FWM
2
Focused Wealth Management
New York
$1K +$758 +9,250 +313%
CCB
3
Cutter & Co Brokerage
Missouri
– -$2K -79,500 Closed

PVCT Hedge Fund Activity: Q1 2017 in Review

3 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q1 2017, worth a combined $5K — up 25% from $4K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of PVCT and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Focused Wealth Management, adding an estimated $758. The largest seller was Cutter & Co Brokerage, exiting entirely with an estimated $2K sold.

  • 3 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q1 2017, down from 8 in Q4 2016.
  • Funds reported $5K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q1 2017, up 25% quarter-over-quarter.
  • 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q1 2017 and 4 closed out, a net change of -4 holders.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q1 2017 was Focused Wealth Management, an estimated $758 added.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q1 2017 was Cutter & Co Brokerage, an estimated $2K sold.

Based on aggregated 13F filings for Q1 2017.